Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus Target Price from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $6.17.

Several analysts have recently weighed in on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a report on Friday, March 21st. JMP Securities began coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Context Therapeutics in a research note on Friday, March 21st. Finally, Citizens Jmp upgraded Context Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 8th.

Context Therapeutics Price Performance

Shares of CNTX stock opened at $0.66 on Monday. The stock’s fifty day simple moving average is $0.83 and its 200 day simple moving average is $1.39. Context Therapeutics has a one year low of $0.64 and a one year high of $2.75. The firm has a market cap of $58.77 million, a price-to-earnings ratio of -0.72 and a beta of 2.06.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, research analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in CNTX. State Street Corp raised its stake in shares of Context Therapeutics by 21.5% during the third quarter. State Street Corp now owns 111,907 shares of the company’s stock worth $219,000 after buying an additional 19,800 shares during the last quarter. Franklin Resources Inc. bought a new stake in shares of Context Therapeutics during the 3rd quarter valued at $3,689,000. Y Intercept Hong Kong Ltd bought a new position in shares of Context Therapeutics in the 3rd quarter worth $89,000. Clear Harbor Asset Management LLC grew its stake in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock worth $61,000 after purchasing an additional 21,804 shares during the period. Finally, MPM Bioimpact LLC acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $15,441,000. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.